ZEVRA THERAPEUTICS INC. - COMMON STOCK

8.0000

02-May-25 15:45:00

15 minutes delayed

Stocks

+0.3600

+4.71%

Today's range

7.6600 - 8.1000

ISIN

N/A

Source

NASDAQ

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

10 Oct 2024 06:30:00 By Nasdaq GlobeNewswire
NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

09 Oct 2024 08:00:00 By Nasdaq GlobeNewswire
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

24 Sep 2024 06:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

20 Sep 2024 11:08:07 By Nasdaq GlobeNewswire
Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

06 Sep 2024 07:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at Upcoming Investor Conferences

29 Aug 2024 06:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights

13 Aug 2024 15:05:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

08 Aug 2024 23:00:03 By Nasdaq GlobeNewswire
Zevra Therapeutics Announces Proposed Public Offering of Common Stock

08 Aug 2024 15:01:00 By Nasdaq GlobeNewswire
Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference

07 Aug 2024 08:34:47 By Nasdaq GlobeNewswire
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

02 Aug 2024 16:50:37 By Nasdaq GlobeNewswire
Zevra Therapeutics to Report Second Quarter 2024 Financial Results

30 Jul 2024 07:38:30 By Nasdaq GlobeNewswire
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

09 Jul 2024 08:00:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Expands Executive Leadership Team

25 Jun 2024 06:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders

18 Jun 2024 06:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting

03 Jun 2024 10:00:00 By Nasdaq GlobeNewswire
Zevra Therapeutics to Participate at Upcoming Investor Events

09 May 2024 06:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

08 May 2024 06:00:01 By Nasdaq GlobeNewswire
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

01 May 2024 06:30:00 By Nasdaq GlobeNewswire
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

29 Apr 2024 06:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.